RT Journal Article
SR Electronic
T1 Proteomic-based stratification of intermediate-risk prostate cancer patients
JF Life Science Alliance
JO Life Sci. Alliance
FD Life Science Alliance LLC
SP e202302146
DO 10.26508/lsa.202302146
VO 7
IS 2
A1 Zhong, Qing
A1 Sun, Rui
A1 Aref, Adel T
A1 Noor, Zainab
A1 Anees, Asim
A1 Zhu, Yi
A1 Lucas, Natasha
A1 Poulos, Rebecca C
A1 Lyu, Mengge
A1 Zhu, Tiansheng
A1 Chen, Guo-Bo
A1 Wang, Yingrui
A1 Ding, Xuan
A1 Rutishauser, Dorothea
A1 Rupp, Niels J
A1 Rueschoff, Jan H
A1 Poyet, Cédric
A1 Hermanns, Thomas
A1 Fankhauser, Christian
A1 Rodríguez Martínez, María
A1 Shao, Wenguang
A1 Buljan, Marija
A1 Neumann, Janis Frederick
A1 Beyer, Andreas
A1 Hains, Peter G
A1 Reddel, Roger R
A1 Robinson, Phillip J
A1 Aebersold, Ruedi
A1 Guo, Tiannan
A1 Wild, Peter J
YR 2024
UL http://www.life-science-alliance.org/content/7/2/e202302146.abstract
AB Gleason grading is an important prognostic indicator for prostate adenocarcinoma and is crucial for patient treatment decisions. However, intermediate-risk patients diagnosed in the Gleason grade group (GG) 2 and GG3 can harbour either aggressive or non-aggressive disease, resulting in under- or overtreatment of a significant number of patients. Here, we performed proteomic, differential expression, machine learning, and survival analyses for 1,348 matched tumour and benign sample runs from 278 patients. Three proteins (F5, TMEM126B, and EARS2) were identified as candidate biomarkers in patients with biochemical recurrence. Multivariate Cox regression yielded 18 proteins, from which a risk score was constructed to dichotomize prostate cancer patients into low- and high-risk groups. This 18-protein signature is prognostic for the risk of biochemical recurrence and completely independent of the intermediate GG. Our results suggest that markers generated by computational proteomic profiling have the potential for clinical applications including integration into prostate cancer management.